NDLI: Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

Please wait, while we are loading the content...

Year: 2017 Volume: 29

Year: 2016 Volume: 28

Year: 2015 Volume: 27

Year: 2014 Volume: 26

Year: 2013 Volume: 25

Year: 2012 Volume: 24

Year: 2011 Volume: 23

Year: 2010 Volume: 22

Year: 2010 Volume: 22 Issue: 6

Year: 2010 Volume: 22 Issue: 5

Year: 2010 Volume: 22 Issue: 4

Year: 2010 Volume: 22 Issue: 3

Year: 2010 Volume: 22 Issue: 2

Prophylactic cranial irradiation in lung cancer.

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope.

Multimodality management of non-small cell lung cancer patients with brain metastases.

Biology and clinical effects of natural killer cells in allogeneic transplantation.

Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.

Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation.

Fungal infections in oncology patients: update on epidemiology, prevention, and treatment.

Can a decisional algorithm be used in first-line treatment of advanced nonsmall cell lung cancer?

Editorial overview: transplantation.

Current world literature.

Year: 2010 Volume: 22 Issue: 1

Year: 2009 Volume: 21

Year: 2008 Volume: 20

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Rosell, Rafael Viteri, Santiago Molina, Miguel Angel Benlloch, Susana Taron, Miquel
Description	Country affiliation: Spain Author Affiliation: Rosell R ( Catalan Institue of Oncology, Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain. rrosell@ico.scs.es)
Abstract	PURPOSE OF REVIEW: Classic activating mutations in the form of deletions in exon 19 or a missense mutation L858R in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) predict dramatic responses to EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib. We review here the clinical benefits of targeted therapy with erlotinib and gefitinib in white and Asian nonsmall-cell lung cancer patients. RECENT FINDINGS: Two separate analyses of pooled data from small phase II prospective studies show that therapy with gefitinib and erlotinib induces responses in over 70% of nonsmall-cell lung cancer patients harboring classic EGFR mutations, with progression-free survival ranging from 9 to 13 months and median survival of around 23 months. Two separate studies in white and Asian patients have recently confirmed that these subgroups of patients attain response rates of 70% with erlotinib and gefitinib, including complete responses, progression-free survival of up to 14 months, and median survival of up to 27 months. The serial monitoring of EGFR mutations in the blood will permit the assessment of molecular responses and be an important tool for the surveillance of clinical progression. SUMMARY: Nonsmall-cell lung cancer with EGFR mutations constitute a new entity with a unique opportunity for further refinement of different genetic subgroups among patients with EGFR mutations, requiring different personalized treatment strategies. Despite the impressive outcomes attained with EGFR tyrosine kinase inhibitors, patients with EGFR mutations at present require continuous treatment, and only a fraction of these patients will reach sustainable long-term survival.
File Format	HTM / HTML
ISSN	10408746
Issue Number	2
Volume Number	22
e-ISSN	1531703X
Journal	Current Opinion in Oncology
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2010-03-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Oncology Carcinoma, Non-small-cell Lung Drug Therapy Lung Neoplasms Protein Kinase Inhibitors Therapeutic Use Receptor, Epidermal Growth Factor Antagonists & Inhibitors Antineoplastic Agents Asian Continental Ancestry Group Genetics Erlotinib Hydrochloride Humans Mutation Quinazolines Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in